JP2020522555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522555A5 JP2020522555A5 JP2019567709A JP2019567709A JP2020522555A5 JP 2020522555 A5 JP2020522555 A5 JP 2020522555A5 JP 2019567709 A JP2019567709 A JP 2019567709A JP 2019567709 A JP2019567709 A JP 2019567709A JP 2020522555 A5 JP2020522555 A5 JP 2020522555A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- icos
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 104
- 102000036639 antigens Human genes 0.000 claims description 104
- 108091007433 antigens Proteins 0.000 claims description 104
- 239000012634 fragment Substances 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 7
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 7
- 102000048776 human CD274 Human genes 0.000 description 7
- 102000043396 human ICOS Human genes 0.000 description 7
- 102000048362 human PDCD1 Human genes 0.000 description 7
- 230000008685 targeting Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517309P | 2017-06-09 | 2017-06-09 | |
| US62/517,309 | 2017-06-09 | ||
| US201862666278P | 2018-05-03 | 2018-05-03 | |
| US62/666,278 | 2018-05-03 | ||
| PCT/IB2018/054167 WO2018225033A1 (en) | 2017-06-09 | 2018-06-08 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522555A JP2020522555A (ja) | 2020-07-30 |
| JP2020522555A5 true JP2020522555A5 (https=) | 2021-07-26 |
Family
ID=62873504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567709A Pending JP2020522555A (ja) | 2017-06-09 | 2018-06-08 | 組み合わせ療法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3634483A1 (https=) |
| JP (1) | JP2020522555A (https=) |
| CN (1) | CN110869049A (https=) |
| BR (1) | BR112019025325A2 (https=) |
| CA (1) | CA3066048A1 (https=) |
| WO (1) | WO2018225033A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| AU2021256652A1 (en) * | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies |
| AU2021256925A1 (en) * | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP2068925A4 (en) | 2007-05-07 | 2011-08-31 | Medimmune Llc | ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP3375791A1 (en) * | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| ES2612914T3 (es) | 2011-03-31 | 2017-05-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra Icos y usos de los mismos |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| EP2744830A4 (en) * | 2012-06-21 | 2015-06-17 | Compugen Ltd | LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| EP2892928B1 (en) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| TWI719970B (zh) | 2015-03-23 | 2021-03-01 | 美商永斯醫療股份有限公司 | 針對ｉｃｏｓ之抗體 |
| EP3331919A1 (en) * | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
-
2018
- 2018-06-08 EP EP18739638.7A patent/EP3634483A1/en not_active Withdrawn
- 2018-06-08 CN CN201880044500.1A patent/CN110869049A/zh active Pending
- 2018-06-08 CA CA3066048A patent/CA3066048A1/en active Pending
- 2018-06-08 JP JP2019567709A patent/JP2020522555A/ja active Pending
- 2018-06-08 BR BR112019025325-4A patent/BR112019025325A2/pt not_active IP Right Cessation
- 2018-06-08 WO PCT/IB2018/054167 patent/WO2018225033A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522555A5 (https=) | ||
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2017537892A5 (https=) | ||
| JP2017537090A5 (https=) | ||
| US20170354623A1 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP2020529421A (ja) | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ | |
| JP2016520082A5 (https=) | ||
| JP2016525117A5 (https=) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| US20190183825A1 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| KR20230165876A (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| Nguyen et al. | A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer | |
| CA2949327A1 (en) | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers | |
| JP7374765B2 (ja) | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 | |
| Mendelsohn | Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic | |
| Gameiro et al. | Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| JP2019524706A5 (https=) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| US20220387529A1 (en) | Treatment for primary and metastatic cancer | |
| JP2021504329A5 (https=) | ||
| JP2024518641A (ja) | 医薬物組合せ及びその使用 | |
| Cimino et al. | Safety considerations with new treatment regimens for anal cancer | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| US20210214442A1 (en) | Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination |